| Patents for A61P 5 - Drugs for disorders of the endocrine system (28,908) |
|---|
| 01/30/2003 | WO2002007765A3 REGULATORS OF PPARδ(β) AND THEIR USE IN THE TREATMENT OF OBESITY AND INSULIN RESISTANCE |
| 01/30/2003 | WO2002002634A3 Human extracellular matrix and cell adhesion polypeptides |
| 01/30/2003 | WO2002000617A3 Selective androgen receptor modulators and methods for their identification, design and use |
| 01/30/2003 | WO2001090359A3 G-protein coupled receptors |
| 01/30/2003 | US20030022939 4-Fluoro-N- indan-2-yl benzamide and its use as a pharmaceutical |
| 01/30/2003 | US20030022901 Serotonergic agents |
| 01/30/2003 | US20030022890 Heterocyclic dihydropyrimidine compounds |
| 01/30/2003 | US20030022885 Pyrazole compounds useful as protein kinase inhibitors |
| 01/30/2003 | US20030022874 New 17-halogenated 19-nor steroids, preparation process and intermediates, use as medicaments and the pharmaceutical compositions containing them |
| 01/30/2003 | US20030022161 Diagnosing mammary gland cancer in humans; obtain ductal fluid sample, monitor marker gene product expression, amplified concentrations of marker products indicates cancer |
| 01/30/2003 | US20030021787 In situ therapy; sustained release |
| 01/30/2003 | US20030021763 Method for the treatment and/or prophylaxis of diseases caused by IL-12 |
| 01/30/2003 | CA2682251A1 A synergistic pharmaceutical combination for the prevention or treatment of diabetes |
| 01/30/2003 | CA2454418A1 Compositions and methods for use of bioactive agents derived from sulfated and sulfonated amino acids |
| 01/30/2003 | CA2453967A1 Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells |
| 01/30/2003 | CA2453965A1 Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells |
| 01/30/2003 | CA2452678A1 Combination of eplerenone and an hmg coa reductase inhibitor |
| 01/30/2003 | CA2452009A1 Chemical compounds |
| 01/30/2003 | CA2451530A1 Chemical compounds |
| 01/30/2003 | CA2450437A1 1-phenylsulphonyl-1,3-dihydro-2h-indol-2-one derivatives, their preparation and their therapeutic application |
| 01/29/2003 | EP1279744A2 Identification and use of molecules implicated in pain |
| 01/29/2003 | EP1279404A1 Use of HIV-1 tat, fragments or derivatives thereof, to target or to activate antigen-presenting cells, to deliver cargo molecules for vaccination or to treat other diseases |
| 01/29/2003 | EP1278846A2 Cytoskeleton-associated proteins |
| 01/29/2003 | EP1278827A2 Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof |
| 01/29/2003 | EP1278772A2 Glucagon antagonists |
| 01/29/2003 | EP1278767A1 Albumin fusion proteins |
| 01/29/2003 | EP1278748A2 Inhibitors of human phosphatidyl-inositol 3-kinase delta |
| 01/29/2003 | EP1278544A2 Albumin fusion proteins |
| 01/29/2003 | EP1278523A2 Combination of progesterone and mifepristone for cancer therapy |
| 01/29/2003 | EP1278502A2 Protease inhibitors |
| 01/29/2003 | EP1119334B1 Two chamber cartridge for atomizers |
| 01/29/2003 | EP1024815B1 Pharmaceutical compositions for oral administration of molecular iodine |
| 01/29/2003 | CN1394142A Use of cyclic ether for preparation of medicaments affecting glucose tolerance |
| 01/29/2003 | CN1394141A Fulvestrant formulation |
| 01/29/2003 | CN1394138A Hair growth stimulant |
| 01/29/2003 | CN1393265A Method for reducing fasting blood-glucose of diabetic and weight |
| 01/28/2003 | US6512002 Methods of treatment for premature ejaculation in a male |
| 01/28/2003 | US6511986 Method of treating estrogen receptor positive carcinoma |
| 01/28/2003 | CA2094300C Steroid derivatives for the treatment of prostatic hypertrophy, their preparation and uses |
| 01/27/2003 | CA2391216A1 Identification and use of molecules implicated in pain |
| 01/23/2003 | WO2003006993A2 Gel compositions |
| 01/23/2003 | WO2003006063A2 Formulation comprising fulvestrant |
| 01/23/2003 | WO2003006049A1 Gonadotropin releasing hormone antagonists in gel-forming concentrations |
| 01/23/2003 | WO2003006027A1 Combination of drospirenone and an estrogen sulphamate for hrt |
| 01/23/2003 | WO2003005960A2 Novel bicyclic and tricyclic cannabinoids |
| 01/23/2003 | WO2002088143A3 Dihydroimidazo[4,5-e]indole and 7h-pyrrolo[3,2-f]quinoxaline derivatives as nicotinic acetylcholine receptor ligands and/or serotonergic ligands |
| 01/23/2003 | WO2002066475A3 Tricyclic androgen receptor modulator compounds |
| 01/23/2003 | WO2002050066A3 Pyrazole compounds useful as protein kinase inhibitors |
| 01/23/2003 | WO2002041835A3 Estrogen receptor modulators |
| 01/23/2003 | WO2002036741A3 Polynucleotide encoding an activated human t-lymphocyte-derived protein related to ubiquitin conjugating enzyme |
| 01/23/2003 | WO2002013798A3 Treatment of the insulin resistance syndrome with selective cgmp pde5 inhibitors |
| 01/23/2003 | WO2002010363A3 Protein phosphatases |
| 01/23/2003 | US20030018984 IGF-I expression system and methods of use |
| 01/23/2003 | US20030018207 Pharmaceutical medication associated with insulin resistance; patient with prophylaxis conditions having reduced sensitivity to insulin |
| 01/23/2003 | US20030018072 Utilization of dialkylfumarates |
| 01/23/2003 | US20030018067 Cardiovascular disorders; anticancer agents |
| 01/23/2003 | US20030018060 Therapeutic methods and compositions involving isoflavones |
| 01/23/2003 | US20030018041 Spiroindene and spiroindane compounds |
| 01/23/2003 | US20030018024 Biphenyl vasopressin agonists |
| 01/23/2003 | US20030017151 Receptor Activator of NF-kappa B antagonists; treatment of medical conditions that require the formation of new bone. |
| 01/23/2003 | US20030017148 Prevention of insulin-dependent diabetes, complications thereof, or allograft rejection by inhibition of cyclooxygenase-2 activity |
| 01/23/2003 | CA2777199A1 Methods and materials for the treatment of testosterone deficiency in men |
| 01/22/2003 | EP1277729A1 Ppar (gamma) modulators |
| 01/22/2003 | EP1276872A2 A thymus expressed human cytochrome p450 (p450tec) |
| 01/22/2003 | EP1276867A2 Regulation of human latrophilin-like g protein-coupled receptor |
| 01/22/2003 | EP1276856A1 Albumin fusion proteins |
| 01/22/2003 | EP1276849A2 Albumin fusion proteins |
| 01/22/2003 | EP1276764A1 Human polynucleotides, polypeptides, and antibodies |
| 01/22/2003 | EP1276738A1 2-amino-3-(alkyl)-pyrimidone derivatives as gsk3.beta. inhibitors |
| 01/22/2003 | EP1276495A1 Novel use of pulmonary surfactant for the prophylaxis or early treatment of acute pulmonary diseases |
| 01/22/2003 | EP1276483A2 Compositions and methods for treating amyloidosis using sulphonate derivatives |
| 01/22/2003 | EP1165537B1 Hydroxymatairesinol in cancer prevention |
| 01/22/2003 | EP1107738A4 Novel pharmaceutical salt form |
| 01/22/2003 | CN1392875A Condensed azepines as vasopressino agonists |
| 01/21/2003 | US6509443 Amino acid residue located at position 63 of native-sequence human Insulin like Growth Factor-I is replaced with an alanine residue or amino acid residues at positions 1 and 70 are replaced with serine and valine respectively |
| 01/21/2003 | US6509376 Utilization of dialkyfumarates |
| 01/21/2003 | US6509318 TGF-B inhibitors and methods |
| 01/21/2003 | US6508585 Differential scanning calorimeter |
| 01/16/2003 | WO2003005035A1 Chp for use as marker for sepsis-type inflammatory diseases |
| 01/16/2003 | WO2003004608A2 Drug metabolizing enzymes |
| 01/16/2003 | WO2003004498A1 Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
| 01/16/2003 | WO2003004492A1 Isoxazolyl-pyrimidines as inhibitors of src and lck protein kinases |
| 01/16/2003 | WO2003004488A1 Indazole benzimidazole compounds as tyrosine and serine/threonine kinase inhibitors |
| 01/16/2003 | WO2003004036A1 Medicinal compositions for treating secondary parathyroid hyperfunction and remedies for cardiovascular complications in association with treatment for secondary parathyroid hyperfunction |
| 01/16/2003 | WO2003004028A1 Tetrahydroquinoline derivatives |
| 01/16/2003 | WO2003003986A2 Parathyroid hormone antibodies and related methods |
| 01/16/2003 | WO2002067893A3 Pharmaceutical formulation comprising bicalutamide |
| 01/16/2003 | WO2002031109A3 Intracellular delivery of biological effectors by novel transporter peptide sequences |
| 01/16/2003 | WO2002011715A3 The use of benzylideneaminoguanidines and hydroxyguanidines as melanocortin receptor ligands |
| 01/16/2003 | US20030013756 Hormone inhibitor; sexual disorders |
| 01/16/2003 | US20030013754 Antiinflamamtory agents |
| 01/16/2003 | US20030013720 Antidiabetic agents; obesity |
| 01/16/2003 | US20030013708 Therapeutic heterocyclic compounds |
| 01/16/2003 | US20030013691 2-ethyl and 2-ethylidene-19-nor-vitamin D compounds |
| 01/16/2003 | US20030013654 Administering polypeptide |
| 01/16/2003 | CA2453075A1 Drug metabolizing enzymes |
| 01/16/2003 | CA2452603A1 Isoxazolyl-pyrimidines as inhibitors of src and lck protein kinases |
| 01/15/2003 | EP1274849A2 Protein phosphatases |
| 01/15/2003 | EP1274720A1 Albumin fusion proteins |
| 01/15/2003 | EP1274719A2 Albumin fusion proteins |